ClinicalTrials.gg
CompletedNCT04444778Updated Oct 7, 2026

Intermitent Hypoxia and Its Pathophysiology Consequences in the Sleep Apnea-Hypopnea Syndrome.

An interventional study of CPAP in Sleep Apnea, Obstructive, sponsored by Alberto Alonso Fernandez. Completed at 2 sites in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Alberto Alonso Fernandez · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Sleep Apnea, Obstructive with a site in Spain — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Spain.

Enrollment
29th of 60
130 · median 128
Started
2020
with 4 others
No phase
46 of 82
6 open now
Registered
52nd of 82
by date
Lead sponsor
2 of 82
Alberto Alonso Fernandez

Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, this one is the 29th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2020, is one of 46 with no phase, and was the 52nd registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

16 of the 82 studies in Sleep Apnea, Obstructive with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Sleep Apnea, Obstructive with a site in Spain, or all of them as a file.
02

Study summary

Clinical trial on the effect of continuous positive pressure (CPAP). Objectives: 1) To assess the total or partial recovery of oxidative and inflammatory damage after recovering IH. 2) To check whether the results obtained in vitro on the recovery of the damage according to the form of manifestation of IH are validated in SAHS patients. 3) To determine if CPAP reduces nighttime blood pressure and arterial stiffness depending on whether or not patients have a non-dipping pattern of blood pressure and depending on the degree of correction of IH. 4) To clarify whether residual nocturnal hypoxemia influences the recovery of oxidative and inflammatory damage in patients. 5) To determine nasal and intestinal microbioma and the effect of CPAP treatment

Read the detailed description

Design: Randomized, parallel group, non-blinded, controlled clinical trial compared with conventional treatment.

A. Protocol and intervention Patients with an AHI>30 h-1 will be assigned, using a 1:1 randomization table, to lifestyle recommendations treatment or to lifestyle recommendations plus nasal CPAP, for a period of 4 months. CPAP pressure will be titled with automatic using an AutoSet II device, ResMed.

B. Sample size For the estimation of the sample size, previous data from our group were used. In this case, in order to compare the effect of CPAP in a subgroup of patients with well-controlled OSA and in another with residual hypoxemia; it would be necessary to randomize a total of 100 patients with OSA.

C. Ethical considerations

  • Indication of CPAP treatment for the prevention of cardiovascular morbidity and mortality in OSA patients without daytime sleepiness is not yet accepted.
  • Those patients with a urgent study indication for the diagnosis and treatment of respiratory sleep disorders (professional drivers, respiratory failure or risk professions) will be excluded from the project. In the other cases, the delay in healthcare for the performance of Polysomnography and CPAP titration exceeds the duration of the study, therefore that patients assigned to the control arm (conventional treatment) will not be exposed to a higher risk than the general population.

D. Methods

  • Polysomnography. It will be used as a screening test previous the randomization of the included patients. The exploration and its interpretation will be carried out following the recommendations of the American Academy of Sleep Medicine. Based on the results of this test, only those patients with an AHI will continue in the study when AHI >30 h-1. In these patients the determinations listed below will be carried out immediately before randomization (visit 1), at 4 weeks (visit 2), 16 weeks (visit 4) of allocation to the corresponding treatment group
  • Clinical data: The medication used and other associated diseases already diagnosed will be recorded.
  • Vital signs: recording of blood pressure, by means of a conventional triple taking, and heart rate.
  • Anthropometric characteristics: age and weight in basal conditions, the perimeter of the neck and waist / hip index will be measured. The lean mass index will be determined using a Bodystat 1500 impedance system (Bodystat Ltd, United Kingdom).
  • Questionnaires: Epworth Sleepiness Scale, generic health-related quality of life (SF-12 and EuroQoL) and daily physical activity (International Physical Activity Questionnaire or iPAQ).
  • Laboratory findings: blood count, coagulation, creatinine, serum sodium and potassium; glycated hemoglobin (HbA1c) and blood glucose and insulin levels in fasting, from these values will determine the resistance and sensitivity to insulin using the HOMA and QUICKI indices; total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides; and troponin I, homocysteine, NT-pro BNP and highly sensitive C-reactive protein.
  • Blood venous samples. 20 mL of venous blood will be collected, storing the plasma obtained at -80 ºC for subsequent determination of inflammatory markers (IL-1ß, IL-6, IL-8, HIF 1- a and TNF-a), oxidative stress (8-isoprostane), endothelial damage (endothelin, angiotensin), and appetite-regulating hormones (leptin and adiponectin).
  • Plasma proteins from peripheral blood samples will be analyzed using a high-throughput multiplex immunoassay technology based on the Proximity Extension Assays (PEA) (OLINK Bioscience, Uppsala, Sweden). Olink (OLINK Bioscience, Uppsala, Sweden).
  • Night pulse oximetry. To assess the existence of residual nocturnal hypoxemia.
  • Arterial stiffness. According to the recommendations by Sphygmo-Corsystem (version 7, AtCor Medical, Sydney, Australia).
  • Study of the gut and pharyngeal microbiota by massive sequencing (next generation sequencing) after PCR amplification of the 16S rRNA gene, paired-end sequencing with Illumina technology (16S Amplicon and XT Nextera Metagenomic) and subsequent metataxonomic analysis of the microbial populations.
  • Ambulatory blood pressure monitoring (ABPM) with Mortara's Ambulo 2400 ambulatory blood pressure device.
  • In the patients assigned to the CPAP treatment arm, a count of the hours of use of the CPAP will be carried out at each visit by directly reading the automatic counter of each equipment.

Statistic analysis The data will be expressed as mean ± standard deviation, median (interquartile range) or percentage, depending on their type and distribution. For comparison between groups Student's t-test, the U-Mann-Whitney or the chi-square test will be used, as appropriate. The relations between variables will be analyzed using Pearson's correlation and multiple linear regression analysis. The effect of treatment will be evaluated using analysis of covariance (ANCOVA) to compare the change in log-transformed 8-isoprostane for the CPAP versus the usual care group, with the treatment group as a factor, and baseline 8-isoprostane, body mass index, smoking, and age as covariates. Intention-to-treat analysis included all randomized patients, whereas the per-protocol analysis set was defined as all patients in the full analysis who completed the study and, in the group treated with CPAP, achieved adherence greater than 4 hours per night. A multiple logistic regression model will be applied to determine the related variables with a response to treatment. Values of p \<0.05 will be considered statistically significant. The statistical study will be performed with the SPSS program version 15.0.

03

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • sleep apnea syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cases: patients with AHI > 30
  • Controls: subjects with AHI \< 5 and Epworth >10

Exclusion criteria

Exclusion Criteria:

  • Epworth>18
  • \<40Kg/M2
  • Arterial Hypertension
  • Mellitus Diabetes
  • Cerebrovascular disease
  • Ischemic heart disease
  • Cardiac arrhythmia
  • Chronic cardiovascular diseases
  • Daytime Oxygen saturation>95%
  • Risk professions (professional drivers)
  • Concomitant treatment with antihypertensives, statins, antidiabetics, beta-blockers or systemics .
  • Pretreatment with CPAP.
  • Participation in another clinical trial thirty days prior to randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Active comparator
    Continuous positive airway pressure

    Diet and general life style recommendations plus continuous positive airway pressure (CPAP).

    Device: CPAP

  • No intervention
    Conservative treatment

    Diet and general life style recommendations.

Interventions

  • DeviceCPAP

    Continuous positive airway pressure

06

What researchers measure

Primary outcomes

  1. Change from baseline in 8 isoprostane levels

    To compare the change in 8 isoprostane levels between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  2. Change from baseline in microbiota population diversity from stool samples

    To compare the change in in microbiota population diversity, after massive sequencing and amplification of the 16S rRNA gene from stool samples between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  3. Change from baseline in microbiota population diversity from nasopharyngeal samples

    To compare the change in microbiota population diversity, after massive sequencing and amplification of the 16S rRNA gene from nasopharyngeal samples between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  4. Change from baseline in microbiota population abundance from stool samples

    To compare the change in microbiota population abundance, after massive sequencing and amplification of the 16S rRNA gene from stool samples between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  5. Change from baseline in microbiota population abundance from nasopharyngeal samples

    To compare the change in microbiota population abundance, after massive sequencing and amplification of the 16S rRNA gene from nasopharyngeal samples between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  6. Change from baseline in microbiota population color maps from stool samples

    To compare the change in microbiota population color maps, after massive sequencing and amplification of the 16S rRNA gene from stool samples between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  7. Change from baseline in microbiota color maps from nasopharyngeal samples

    To compare the change in microbiota population color maps, after massive sequencing and amplification of the 16S rRNA gene from nasopharyngeal samples between the patients allocated to CPAP group and the control group

    Time frame: 4 months

Secondary outcomes

  1. Augmentation index (%)

    To compare Augmentation index (%) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  2. Pulse wave velocity (m/sec)

    To compare pulse wave velocity (m/sec) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  3. Aortic systolic blood pressure central (mmHg)

    To compare systolic blood pressure central (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  4. Diastolic blood pressure central (mmHg)

    To compare diastolic blood pressure central (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  5. Subendocardial viability ratio (%)

    To compare subendocardial viability ratio (%) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  6. Central augmentation pressure (mmHg)

    To compare central augmentation pressure (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  7. Time to reflection (ms)

    To compare time to reflection (ms) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  8. Peripheral systolic blood pressure (mmHg)

    To compare peripheral systolic blood pressure (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  9. Peripheral diastolic blood pressure (mmHg)

    To compare diastolic blood pressure central (mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  10. Nocturnal blood pressure dipping

    To compare number of patients with nocturnal blood pressure dipping in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  11. Nocturnal hypertension.

    To compare number of patients with nocturnal hypertension in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  12. Patients with undiagnosed hypertension

    To compare number of patients with undiagnosed hypertension in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  13. C-reactive protein (CRP)

    To compare CRP in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  14. Homocysteine

    To compare homocysteine (μmol/L) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  15. Endothelin

    To compare endothelin levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  16. Angiotensin

    To compare angiotensin levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group

    Time frame: Baseline and 4 months

  17. 8 isoprostane levels in OSA and in non-OSA patients

    To compare 8 isoprostane levels in OSA and in non-OSA patients.

    Time frame: Baseline

  18. Lipid profile

    To compare lipid profile with same units of measure (all in mg/dL) in OSA and in non-OSA patients and to compare baseline (OSA vs. non-OSA), and the change from baseline in lipid profile between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  19. Circulating inflammatory proteomic profile in OSA

    To compare the circulating inflammatory proteomic profile using proximity expression assay technology (Olink®, Sweden, which comprised 96 proteins. All data are expressed as normalized protein expression values) in OSA and in non-OSA patients and to compare the change from baseline the circulating inflammatory proteomic profile between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  20. Systemic inflammation.

    To compare systemic inflammation (IL1bbeta IL-6, IL-8, HIF1 alpha, TNF-1alpha) with same units of measure (all in pg/mL) in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  21. Intake-regulating hormones.

    To compare intake-regulating hormones with same units of measure (all in µg/mL) in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  22. Change from baseline in number of patients with desaturation index >3%

    To compare the change from baseline in number of patients with desaturation index ≥ 5 h-1, ≥ 15 h-1, and ≥ 30 h-1 between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  23. Microbiota population abundance from stool and nasopharyngeal samples in OSA and in non-OSA patients

    To compare microbiota population abundance from stool and nasopharyngeal samples in OSA and in non-OSA patients

    Time frame: Baseline

  24. Microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients

    To compare microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients

    Time frame: Baseline

  25. Microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients

    To compare microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients

    Time frame: Baseline

  26. Relationships of microbiota population diversity from stool and nasopharyngeal samples in OSA to blood pressure profile.

    To relate microbiota population diversity from stool and nasopharyngeal samples to blood pressure profile.

    Time frame: Baseline and 4 months

  27. Relationships of microbiota population abundance from stool and nasopharyngeal samples in OSA to blood pressure profile

    To relate microbiota population diversity from stool and nasopharyngeal samples to blood pressure profile.

    Time frame: Baseline and 4 months

  28. Relationships of microbiota population color maps from stool and nasopharyngeal samples in OSA to blood pressure profile

    To relate microbiota population color maps from stool and nasopharyngeal samples to blood pressure profile.

    Time frame: Baseline and 4 months

  29. Relationships of microbiota population diversity from stool and nasopharyngeal samples in OSA to augmentation index.

    To relate microbiota population diversity from stool and nasopharyngeal samples to augmentation index.

    Time frame: Baseline and 4 months

  30. Relationships of microbiota population abundance from stool and nasopharyngeal samples in OSA to augmentation index.

    To relate microbiota population diversity from stool and nasopharyngeal samples to augmentation index.

    Time frame: Baseline and 4 months

  31. Relationships of microbiota population color maps from stool and nasopharyngeal samples in OSA to augmentation index.

    To relate microbiota population color maps from stool and nasopharyngeal samples to augmentation index.

    Time frame: Baseline and 4 months

  32. Relationships of microbiota population diversity from stool and nasopharyngeal samples in OSA to pulse wave velocity.

    To relate microbiota population diversity from stool and nasopharyngeal samples to pulse wave velocity.

    Time frame: Baseline and 4 months

  33. Relationships of microbiota population abundance from stool and nasopharyngeal samples in OSA to pulse wave velocity.

    To relate microbiota population diversity from stool and nasopharyngeal samples to pulse wave velocity.

    Time frame: Baseline and 4 months

  34. Relationships of microbiota population color maps from stool and nasopharyngeal samples in OSA to pulse wave velocity.

    To relate microbiota population color maps from stool and nasopharyngeal samples to pulse wave velocity.

    Time frame: Baseline and 4 months

  35. Vitamin D

    To compare Vitamin D levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group

    Time frame: Baseline and 4 months

  36. Glucose metabolism indices

    To compare glucose metabolism indices \[(hemoglobin A1c, fasting insulin level, homeostasis model assessment of insulin resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKY) and triglyceride-glucose index, triglyceride glucose-waist circumference, triglyceride glucose-Body Mass index\] in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group

    Time frame: Baseline and 4 months

  37. Hematological prognostic biomarkers

    To compare neutrophil to lymphocyte, hemoglobin-to-red cell distribution width in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  38. Obesity indices

    To compare body mass index, body fat composition in OSA and in non-OSA patients and to compare the change from baseline between the patients allocated to CPAP group and the control group

    Time frame: Baseline and 4 months

  39. Ambulatory blood pressure monitoring (mmHg)

    To compare 24-hour (systolic blood pressure, diastolic blood pressure, mean blood pressure, daytime systolic blood pressure, daytime diastolic blood pressure, daytime mean blood pressure, nighttime systolic blood pressure, nighttime diastolic blood pressure, nighttime mean blood pressure) (all in mmHg) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group

    Time frame: Baseline and 4 months

  40. Nocturnal oxygenation indices

    To compare (oxygen desaturación index, time spent with oxygen saturation below 90%) in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  41. Change from baseline in number of patients with Obesity

    To compare the change from baseline in number of patients with obesity and abdominal obesity between the patients allocated to CPAP group and the control groups

    Time frame: 4 months

  42. Daytime hypersomnolence

    To compare Epworth sleepiness scale (ESS) and number of patients with ESS \>10 in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and the control group.

    Time frame: Baseline and 4 months

  43. Change from baseline in number of patients with metabolic syndrome or prediabetes

    To compare the change from baseline in number of patients with metabolic syndrome and prediabetes profile between the patients allocated to CPAP group and the control group

    Time frame: 4 months

07

Study locations

2 sites
  • Hospital Son Espases
    Palma, Balearic Islands 07006, Spain
  • Hospital Son Llatzer
    Palma, Balearic Islands 07006, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Oct 2026, 74 months.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 74 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Apr 2025 → Oct 2026 and completion May 2025 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2020
First posted
Jun 24, 2020
StartActual
Jul 20, 2020
Primary completionActual
Oct 1, 2026was Apr 2025
CompletionActual
Oct 2, 2026was May 2025
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 7, 2026
Primary completion
Apr 16, 2025→Oct 1, 2026
Oct 7, 2026
Study completion
May 6, 2025→Oct 2, 2026 (actual)
Oct 7, 2026
Secondary outcomes
10 added, 2 description edited
What changed in the outcomes
  • AddedAngiotensinTime frame: Baseline and 4 months
  • AddedVitamin DTime frame: Baseline and 4 months
  • AddedGlucose metabolism indicesTime frame: Baseline and 4 months
  • AddedHematological prognostic biomarkersTime frame: Baseline and 4 months
  • AddedObesity indicesTime frame: Baseline and 4 months
  • AddedAmbulatory blood pressure monitoring (mmHg)Time frame: Baseline and 4 months
  • AddedNocturnal oxygenation indicesTime frame: Baseline and 4 months
  • AddedChange from baseline in number of patients with ObesityTime frame: 4 months
  • AddedDaytime hypersomnolenceTime frame: Baseline and 4 months
  • AddedChange from baseline in number of patients with metabolic syndrome or prediabetesTime frame: 4 months
  • DescriptionChange from baseline in number of patients with desaturation index >3%: how it is measured was reworded
  • DescriptionSystemic inflammation.: how it is measured was reworded
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Enrolling by invitation→Completed
    Primary completion Apr 16, 2025→Oct 1, 2026
    Study completion May 6, 2025→Oct 2, 2026 (now actual)
    Secondary outcomes 10 added, 2 description edited
    What changed in the outcomes
    • AddedAngiotensinTime frame: Baseline and 4 months
    • AddedVitamin DTime frame: Baseline and 4 months
    • AddedGlucose metabolism indicesTime frame: Baseline and 4 months
    • AddedHematological prognostic biomarkersTime frame: Baseline and 4 months
    • AddedObesity indicesTime frame: Baseline and 4 months
    • AddedAmbulatory blood pressure monitoring (mmHg)Time frame: Baseline and 4 months
    • AddedNocturnal oxygenation indicesTime frame: Baseline and 4 months
    • AddedChange from baseline in number of patients with ObesityTime frame: 4 months
    • AddedDaytime hypersomnolenceTime frame: Baseline and 4 months
    • AddedChange from baseline in number of patients with metabolic syndrome or prediabetesTime frame: 4 months
    • DescriptionChange from baseline in number of patients with desaturation index >3%: how it is measured was reworded
    • DescriptionSystemic inflammation.: how it is measured was reworded
    + 4 other changes: index terms, verification date, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04444778
Lead sponsor
Alberto Alonso Fernandez
Collaborators
Instituto de Salud Carlos III
Responsible party
Alberto Alonso Fernandez (Principal investigator, Fundació d'investigació Sanitària de les Illes Balears) — Sponsor-investigator
First posted
Jun 24, 2020
Start date
Jul 20, 2020
Primary completion
Oct 1, 2026
Completion
Oct 2, 2026
Last update
Oct 7, 2026

Study contacts

Alberto Alonso, Dr
principal investigator · Fundació d'investigació Sanitària de les Illes Balears

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion